Get the Stockscreener App
5.18
1.17%
0.06
After Hours:
5.17
-0.010
-0.19%
Journey Medical Corp stock is traded at $5.18, with a volume of 111.87K.
It is up +1.17% in the last 24 hours and up +4.65% over the past month.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
See More
Previous Close:
$5.12
Open:
$5.2
24h Volume:
111.87K
Relative Volume:
0.55
Market Cap:
$141.65M
Revenue:
$61.86M
Net Income/Loss:
$-11.43M
P/E Ratio:
-10.75
EPS:
-0.4818
Net Cash Flow:
$-12.52M
1W Performance:
-1.52%
1M Performance:
+4.65%
6M Performance:
-41.40%
1Y Performance:
-24.60%
1-Day Range:
$5.04
$5.24
1-Week Range:
$4.85
$5.3499
52-Week Range:
$4.31
$9.555
Journey Medical Corp Stock (DERM) Company Profile
Name
Journey Medical Corp
Sector
Phone
480-434-6670
Address
9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE
Compare DERM vs TAK, ZTS, TEVA, HLN, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DERM
Journey Medical Corp
|
5.18 | 140.01M | 61.86M | -11.43M | -12.52M | -0.4818 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Journey Medical Corp Stock (DERM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-25-25 | Initiated | H.C. Wainwright | Buy |
| Jul-30-25 | Resumed | B. Riley Securities | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-28-24 | Resumed | ROTH MKM | Buy |
| Dec-07-21 | Initiated | B. Riley Securities | Buy |
Journey Medical Corp Stock (DERM) Latest News
Assertio (ASRT) Moves 17.0% Higher: Will This Strength Last? - Yahoo Finance
Fortress Biotech CEO to speak at royalty company virtual conference - Stock Titan
10 Best Travel Insurance Companies For 2026 - Forbes
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical CorporationDERM - ChartMill
Journey Medical (NASDAQ: DERM) details 2026 virtual meeting, board and pay - Stock Titan
Vanguard reports 1.21M-share stake in Journey Medical Corp (DERM) - Stock Titan
FBIO Stock Price, Quote & Chart | FORTRESS BIOTECH INC (NASDAQ:FBIO) - ChartMill
Q1 EPS Estimates for Journey Medical Cut by HC Wainwright - MarketBeat
Journey Medical Corporation (NASDAQ:DERM) Receives Average Rating of "Hold" from Analysts - MarketBeat
Journey Medical (DERM) COO receives new RSU and option grants - Stock Titan
Journey Medical (DERM) CFO receives new RSU and stock option grants - Stock Titan
Journey Medical (DERM) CEO granted RSUs and stock options - Stock Titan
Q4 EPS Estimates for Journey Medical Raised by HC Wainwright - MarketBeat
Journey Medical Expands Emrosi™ Coverage to Over 150 Million Commercial Lives with Third Major GPO Contract - Minichart
DERM Financials: Income Statement, Balance Sheet & Cash Flow | Journey Medical Corp - Stock Titan
Journey Medical Expands Emrosi Commercial Access Across U.S. - TipRanks
Journey Medical expands Emrosi payer access to 85% of US commercial lives - TradingView
Emrosi access reaches 85% of U.S. commercial lives at Journey Medical (Nasdaq: DERM) - Stock Titan
Rosacea drug Emrosi expands access to over 150 million U.S. lives - Stock Titan
Danone Sets New Sustainability Targets with Second Phase of Impact Journey - Food & Beverage Outlook
Is Journey Med (DERM) stock a favorable investment idea | Q4 2025: EPS Beats ForecastsCrowd Entry Signals - Newser
Stock List: Research Stocks from Around the World - GuruFocus
Journey Medical Corporation (NASDAQ:DERM) Short Interest Up 31.3% in March - MarketBeat
Journey Medical Corp stock (US48113J1007): Why does its dermatology focus matter more now for U.S. i - AD HOC NEWS
DERM SEC FilingsJourney Medical Corp 10-K, 10-Q, 8-K Forms - Stock Titan
DERM Technical Analysis & Stock Price Forecast - Intellectia AI
Personal trainer shocked to find health company using his photos - BBC
Journey Medical Corp stock: What investors need to know amid volatility - AD HOC NEWS
Wasatch Advisors holds 2.13M Journey Medical (NASDAQ: DERM) — 10% stake - Stock Titan
DERM Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
DERM Stock Analysis: Journey Medical Corporation trades at $4.64 down 1.07% today - Newser
Journey Medical Corporation (NASDAQ:DERM) Given Consensus Rating of “Hold” by Analysts - Defense World
Journey Medical Corporation (NASDAQ:DERM) Given Consensus Rating of "Hold" by Analysts - MarketBeat
US Stocks Recap: Can Journey Medical Corporation be the next market leaderPortfolio Profit Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Short Squeeze: Can Journey Medical Corporation reach all time highs this year2026 Investor Takeaways & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Rare-disease voucher sale brings Fortress more than $100M - Stock Titan
Why The Journey Medical (DERM) Narrative Is Shifting With New Targets And Going Concern Risks - Yahoo Finance
KALA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Aug Update: Can Journey Medical Corporation reach all time highs this yearWeekly Investment Report & Expert Curated Trade Setups - baoquankhu1.vn
Journey Medical (NASDAQ:DERM) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Journey Medical Corporation (NASDAQ:DERM) Q4 2025 Earnings Call Transcript - Insider Monkey
HC Wainwright Forecasts Journey Medical Q1 Earnings - MarketBeat
Market Pulse: What hedge funds are buying Journey Medical CorporationQuarterly Growth Report & Verified Short-Term Plans - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Icon (ICLR) and Journey Medical Corp (DERM) - The Globe and Mail
Journey Medical (DERM) Q4 Results: Examining Essential Metrics Compared to Projections - Bitget
Journey Medical (DERM) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Journey Medical Corporation 2025 Annual Report: Dermatology Product Portfolio, FDA Approvals, Market Strategy, and Intellectual Property Overview - Minichart
Top movers analysis one hour before the close of the markets on 2026-03-26: top gainers and losers in today's session. - ChartMill
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Journey Medical Corporation Q4 2025 Earnings Call Summary - finance.yahoo.com
HC Wainwright Reaffirms Buy Rating for Journey Medical (NASDAQ:DERM) - marketbeat.com
Journey Medical Corp Stock (DERM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
2.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):